Aurobindo Pharma Ltd.

Law Offices of Gary Martin Hays & Associates, P.C. contact: (470) 294-1674. Law Offices of Mark E. Salomone contact: (857) 444-6468.

Aurobindo Pharma's consolidated net profit rose 9% to Rs 817 crore in Q2FY25, driven by an 8% increase in revenue to Rs 7796 crore. Formulations revenue grew 11.3% to Rs 6640 crore, with US and European markets up 4.3% and 19% respectively. Growth markets revenue surged 44%, while ARV revenue fell 23%. API revenue declined 1% to Rs 1156 crore. The company received 8 final approvals and launched 14 products in Q2FY25.

DelveInsight's 2024 Alzheimer's Disease Pipeline Insight report details 110+ companies developing 120+ therapies, including Neurodon, Sangamo Therapeutics, and others. Key therapies like NRDN-201, ST-501, and Blarcamesine are in various clinical phases. Regulatory milestones include FDA's conventional approval of Leqembi in 2023. The report covers drug mechanisms, clinical studies, and market dynamics.

Aurobindo Pharma's Eugia Steriles Private Limited received FDA approval for Lidocaine Hydrochloride Injection, USP, 1% (10 mg/mL) and 2% (20 mg/mL) at its Andhra Pradesh facility, inspected by the FDA from March 28 to April 5, 2024.